Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Mahashur, D. Talwar, M. Kotnis (Mumbai, Noida, India). Efficacy and safety of omalizumab in real-life practice in India. Eur Respir J 2012; 40: Suppl. 56, 229

Member's Comments

Pavic Michelle - 02.09.2012 11:50
Hello, would it be possible to get a copy of your poster emailed to michelle.pavic@novartis.com? I have found the data to be quite interesting. Thanks.

Related content which might interest you: Italian real-life experience of omalizumab Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 A post-marketing study to evaluate the safety and tolerability of a non-chlorofluorocarbon salbutamol inhaler in asthmatic patients in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 78s Year: 2002 Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018 Clinical efficacy and safety of medical thoracoscopy Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 Clinical and economic outcomes following 52-week add-on omalizumab Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2015; 45: 161-170 Year: 2015 Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2016; 47:1591-1592 Year: 2016 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010 Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies? Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019 Use of Omalizumab in children in real clinical practice. Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021